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Introduction
============

Stereotactic body radiation therapy (SBRT) has emerged as a viable re-irradiation strategy for unresectable locally recurrent previously irradiated squamous cell carcinomas of the head and neck (rSCCHN), with recent multi-institutional comparative effectiveness analyses suggesting less acute toxicity and comparable outcomes when contrasting SBRT to intensity-modulated radiation therapy (IMRT) \[[@REF1]-[@REF2]\]. However, a wide range of dose selection exists across the SBRT literature, amidst the concern of increased toxicity rates with use of higher dose re-irradiation regimens \[[@REF3]\].

The first Phase I dose-escalation trial using SBRT for rSCCHN reported a median overall survival (OS) of six months with no Grade 3/4 toxicities from dose tiers ranging from 25 Gy to 44 Gy \[[@REF4]\]. This data was followed by reports which demonstrated that dose escalation to 50 Gy in five fractions was feasible with SBRT for rSCCHN \[[@REF5]\]. Additionally, studies have shown that SBRT at a median dose of 40 Gy, administered with cetuximab, resulted in superior median survival compared to SBRT alone (24.5 vs. 14.8 months, respectively) and improved patient-reported quality of life \[[@REF6]-[@REF7]\]. 

Despite this data, multiple other studies have utilized a variety of dose regimens between 18 - 50 Gy in anywhere from one to six fractions, demonstrating median survival rates ranging from 6.7 to 13.6 months and one-year OS rates ranging from 38% to 58% \[[@REF8]-[@REF11]\]. Prospective Phase II studies of SBRT and cetuximab have similarly used variable doses of 36 - 50 Gy in five to six fractions \[[@REF12]-[@REF14]\]. As SBRT is pushed forward into the cooperative group setting in studies, such as the NRG KEYSTROKE trial (NCT03546582), the lack of consensus regarding dose selection across treatment settings has led to challenges in both clinical situations and trial design \[[@REF15]\].

The RSSearch® Patient Registry is a recently developed multi-institutional international database designed to expedite the collection of clinical information for patients treated with stereotactic radiosurgery (SRS) or SBRT at community and academic radiotherapy centers. Since 2006, the registry has attained information regarding over 18,000 enrolled patients treated with SRS or SBRT. Previously, the registry has been a useful tool in the examination of outcomes in patients with various forms of cancer treated with SBRT, with results comparable to other investigational studies and research \[[@REF16]-[@REF18]\]. Thus, we aimed to use the RSSearch Patient Registry to compare toxicity, tumor control, and survival across a wide array of clinical practice settings to better guide dose selection. We hypothesized that higher dose selection is associated with improved local control and survival with no significant difference in toxicity.

Materials and methods
=====================

The RSSearch Patient Registry encourages all centers utilizing SBRT as a treatment modality to voluntarily participate in the registry. Prior to participation in the registry, respective Institutional Review Board and Ethics Committee approval is required. Patients are asked for informed consent before having their respective information logged in the registry. No compensation is provided to either providers or patients for participating in RSSearch. Planning of SBRT plans and treatment delivery differed per respective institutional preferences.

The RSSearch Patient Registry was searched for patients with recurrent head and neck cancer (rHNC) of squamous cell histology treated with SBRT between January 2008 to November 2016. Inclusion criteria required that information was available regarding patient and lesion characteristics, treatment dose, and follow-up for survival analysis. Initial gross tumor volume (GTV) and local control (LC) were evaluated either by computed tomography (CT), magnetic resonance imaging (MRI), or positron-emission tomography (PET)/CT as per institutional preference. 

Statistical summaries of the relevant patient and lesion characteristics, in addition to radiotherapy planning, were performed with descriptive analyses. Possible factors impacting LC and OS were identified via the Kaplan-Meier method, with a comparison between groups completed using log-rank t-tests. Prognostic factors that were evaluated included prescription dose and fractionation schedule, tumor location, initial Karnofsky Performance Score (KPS), patient age, and GTV. When examining the benefit of dose escalation, doses of ≥ 40 Gy were compared against doses \< 40 Gy, given prior reports documenting LC benefits with prescription doses of 40 Gy and above for five-fraction SBRT. To account for the study's retrospective design and potential indication bias, a Cox multivariate analysis (MVA) was performed. The MVA was completed first utilizing a forced entry method of all analyzed variables, then as a sensitivity analysis due to the small number of patients relative to the number of variables by means of a parsimonious model formed using a forward selection of only variables significant on univariate analysis. 

The relationship between side-effect incidence and dose escalation was evaluated via logistic regression. Acute toxicities were defined as occurring within three months of the end of treatment and late toxicities as those occurring more than three months following treatment. KPS and pain scores (as measured by the visual analog score (VAS) on a scale of 0 - 10) were examined at the initiation of treatment and compared to their respective scores three months after beginning therapy. Toxicity was scored using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Statistical analyses and figure production was completed with the Statistical Package for the Social Sciences (SPSS) (IBM, Armonk, New York, USA) with a p \< 0.05 considered significant. 

Results
=======

Patient, lesion, and treatment characteristics

Baseline patient characteristics are summarized in Table [1](#TAB1){ref-type="table"}. A total of 45 rHNC patients treated with SBRT from 12 different radiotherapy centers in North America met the study criteria. Thirty-one patients in the cohort also had information regarding LC. Median follow-up was 8.78 months (range: 1 - 59.43 months).

###### Summary of Patient Cohort Characteristics

OS: overall survival; LC: local control; KPS: Karnofsky performance status; VAS: visual analogue scale

  --------------------------------------- -----------------------
  Variable                                 
  Patients with data on OS                45 patients
  Patients with data on LC                31 patients
  Gender                                   
  Male                                    29 patients (64.44%)
  Female                                  16 patients (35.56%)
  Median Age (range)                      69 years (37 - 98)
  Median Initial KPS (range)              80% (20% - 100%)
  Median Initial VAS Pain Score (range)   3.50 (0 - 10)
  Ethnicity                                
  Caucasian                               34 patients (75.56%)
  African American                        4 patients (8.89%)
  Asian                                   2 patients (4.44%)
  Other                                   5 patients (11.11%)
  Prior Treatments for Initial Lesion      
  Surgery                                 18 patients (40.00%)
  Chemotherapy                            32 patients (71.11%)
  Radiation Therapy                       45 patients (100.00%)
  --------------------------------------- -----------------------

Table [2](#TAB2){ref-type="table"} provides information regarding the characteristics of the rHNC lesions, radiotherapy dose, and LC and OS outcomes. The median GTV was 34.09 cc (range: 1.00 - 258.12 cc). One-third of the patients treated with SBRT had lesions involving the nasopharynx. Other common sites included the oropharynx, oral cavity, and tongue. The median prescription dose was 30 Gy (range: 20 - 42.5 Gy). 

###### Summary of Lesion Characteristics and Radiotherapy Planning

GTV: gross tumor volume; LC: local control; OS: overall survival; KPS: Karnofsky performance status; VAS: visual analogue scale; cc: cubic centimeters

  ------------------------------------------------------------ -------------------------
  Variable                                                      
  Median GTV (cc) (range)                                      34.09  (1.00 - 258.12)
  Lesion Location                                               
  Nasopharynx                                                  15 patients (33.33%)
  Gum, floor of mouth, other mouth                             5 patients (11.11%)
  Tongue                                                       9 patients (20.00%)
  Oropharynx                                                   10 patients (22.22%)
  Pharynx/location not specified                               5 patients (11.11%)
  Hypopharynx                                                  1 patient (2.22%)
  Median prescribed dose (range)                               30 Gy (20 Gy - 42.5 Gy)
  Median time to locoregional failure (LRF) (months) (range)   6.07 (1.5 - 59.43)
  Median OS (months) (range)                                   9.23 (0.7 - 59.43)
  Median KPS after treatment (range)                           80% (10% - 100%)
  Patients with rise in KPS                                    3 patients (14.29%)
  Patients with no change in KPS                               17 patients (80.95%)
  Patients with decline in KPS                                 1 patient (4.76%)
  Median VAS pain score after treatment (range)                0 (0 - 10)
  Patients with rise in VAS pain score                         3 patients (13.04%)
  Patients with no change in VAS pain score                    12 patients (52.17%)
  Patients with decline in VAS pain score                      8 patients (34.78%)
  ------------------------------------------------------------ -------------------------

Following SBRT, the median time to locoregional failure (LRF) and the median OS were 6.07 months (range: 1.5 - 59.43 months) and 9.23 months (range: 0.7 - 59.43 months), respectively. One-year LC and OS rates for the cohort were 49.64% (95% confidence interval (CI) = 20.35% - 73.49%) and 37.76% (95% CI = 22.70% - 52.75%), respectively. Median KPS after treatment was unchanged at 80% (range: 10 - 100%). Fourteen percent, 81%, and 5% of the cohort had increases, stabilization, or declines in KPS following SBRT, respectively. Median VAS pain scores declined from 3.50 to zero, with 34.78% of the cohort reporting declines in pain, 52.17% of patients reporting stabilization of pain, and 13% of patients noting pain progression.

Overall survival

A summary of potential prognostic factors and their impact on OS is outlined in Table [3](#TAB3){ref-type="table"}. While no significant difference was noted by factors (such as tumor volume, recurrence site, age, or KPS), patients treated with prescription doses ≥ 40 Gy had a significantly higher one-year OS of 67.79% (95% CI: 34.92% - 86.53%) versus 23.64% (95% CI: 9.66% - 41.07%) when compared with those receiving \< 40 Gy (p = 0.028) (Figure [1](#FIG1){ref-type="fig"}). In order to correct for underlying balances due to retrospective design, an MVA was performed utilizing both forced entry and forward conditional selection methods. Both methods confirmed statistical significance with regards to dose escalation increasing OS (Table [3](#TAB3){ref-type="table"}). On MVA using the forced entry model, prescription doses ≥ 40 Gy for five-fraction SBRT continued to be associated with significantly improved OS {hazard ratio (HR) = 0.45 (95% CI: 0.21 - 0.98; p = 0.045)} when controlling for tumor size, recurrence location, patient age, and patient KPS.

###### Summary of Kaplan-Meier Analyses of Potential Prognostic Factors on One-Year Overall Survival

OS: overall survival; CI: confidence interval; KPS: Karnofsky performance status; GTV: gross tumor volume; SBRT: stereotactic body radiation therapy; cc: cubic centimeters

  ---------------------------------------- -------------------- --------------------------------- ---------
  Variable                                 Number of Patients   1-year OS (95% CI)                p-value
  Initial KPS                                                                                     0.315
  \< 80%                                   15 patients          35.71% (95% CI: 13.03 - 59.44%)    
  ≥ 80%                                    30 patients          39.25% (95% CI: 20.26 - 57.82%)    
  Tumor Location                                                                                  0.202
  Other Locations                          35 patients          42.66% (95% CI: 25.26 - 59.00%)    
  Oropharynx                               10 patients          15.43% (95% CI: 0.77 - 48.83%)     
  Age                                                                                             0.725
  \< 70 years                              25 patients          38.79% (95% CI: 22.07 - 55.24%)    
  ≥ 70 years                               20 patients          29.17% (95% CI: 4.23 - 61.88%)     
  GTV                                                                                              
  \< 25 cc                                 9 patients           25.93% (95% CI: 3.89 - 57.04%)    0.698
  ≥ 25 cc                                  36 patients          40.67% (95% CI: 23.31 - 57.35%)    
  \< 50 cc                                 14 patients          39.68% (95% CI: 14.78 - 63.96%)   0.598
  ≥ 50 cc                                  31 patients          36.71% (95% CI: 18.67 - 54.97%)    
  Prescription Dose (Five-fraction SBRT)                                                          0.028\*
  \< 40 Gy                                 31 patients          23.64% (95% CI: 9.66 - 41.07%)     
  ≥ 40 Gy                                  14 patients          67.79% (95% CI: 34.92 - 86.53%)    
  ---------------------------------------- -------------------- --------------------------------- ---------

![Kaplan-Meier Analysis of Overall Survival Benefit of Dose Escalation for Five-Fraction Stereotactic Body Radiotherapy](cureus-0010-00000003237-i01){#FIG1}

Local control

Table [4](#TAB4){ref-type="table"} depicts the impact of prognostic factors of interest on LC in our cohort. Consistent with findings regarding OS, patients treated to prescription doses ≥ 40 Gy resulted in significantly higher one-year LC rate of 75.00%, (95% CI: 22.48% - 91.83%) compared to the 36.84% one-year LC rate noted in those treated with \< 40 Gy (95% CI: 9.67% - 67.98%, p = 0.030) (Figure [2](#FIG2){ref-type="fig"}). On MVA using forced entry analysis, prescription doses ≥ 40 Gy for five-fraction SBRTcontinued to be associated with significantly improved LC {HR = 0.086 (95% CI: 0.01 - 0.88); p = 0.038)}. Results were confirmed on sensitivity analysis with MVA formed using parsimonious forward selection methods.

###### Summary of Kaplan-Meier Analyses of Potential Prognostic Factors on One-Year Local Control

LC: local control; CI: confidence interval; KPS: Karnofsky performance status; GTV: gross tumor volume; SBRT: stereotactic body radiation therapy; cc: cubic centimeters

  ---------------------------------------- -------------------- --------------------------------- ---------
  Variable                                 Number of Patients   1-year LC (95% CI)                p-value
  Initial KPS                                                                                     0.949
  \< 80%                                   12 patients          62.50% (95% CI: 22.93 - 86.07%)    
  ≥ 80%                                    19 patients          41.27% (95% CI: 7.55 - 73.85%)     
  Tumor Location                                                                                  0.175
  Other Locations                          24 patients          65.34% (95% CI: 34.90 - 84.20%)    
  Oropharynx                               7 patients           53.33% (95% CI: 6.83 - 86.31%)     
  Age                                                                                             0.379
  \< 70 years                              16 patients          54.73% (95% CI: 20.38 - 79.58%)    
  ≥ 70 years                               15 patients          46.67% (95% CI: 7.08 - 80.30%)     
  GTV                                                                                             0.792
  \< 25 cc                                 5 patients           47.39% (95% CI: 19.45 - 68.43%)    
  ≥ 25 cc                                  26 patients          51.84% (95% CI: 21.08 - 75.79%)    
  \< 50 cc                                 8 patients           27.78% (95% CI: 1.00% - 70.04%)   0.700
  ≥ 50 cc                                  23 patients          63.92% (95% CI: 32.59 - 83.64%)    
  Prescription Dose (Five-fraction SBRT)                                                          0.030\*
  \< 40 Gy                                 19 patients          36.84% (95% CI: 9.67 - 67.98%)     
  ≥ 40 Gy                                  12 patients          75.00% (95% CI: 22.48 - 91.83%)    
  ---------------------------------------- -------------------- --------------------------------- ---------
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Toxicities

Treatment-related side-effects (Table [5](#TAB5){ref-type="table"}) were documented in 22.2% of all cases (10/45 patients) with 20% and 8.89% of patients reporting acute and late toxicities, respectively. The majority of patients reported CTCAE Grade 1 (66.6%) or Grade 2 (25.0%) toxicities for 11 unique side-effects among the 10 patients reporting treatment-related toxicities. Of the acute toxicities, 50% were of Grade 1 and 37.5% were of Grade 2, and there was one incidence of an acute Grade 3 esophagitis reported two months following completion of SBRT. All patient-reported late toxicities were of Grade 1. The most commonly reported side-effects were fatigue and dermatitis. Dose escalation was associated with a higher likelihood of treatment-related toxicities for patients treated and doses ≥ 40 Gy (33.33%) as compared to \< 40 Gy (13.33%; p = 0.015).

###### Summary of Patient-Reported Toxicities by Common Terminology Criteria for Adverse Events Grade

  --------------------------------------- ------------------------------------- ---------------------------------
  Grade 1 Toxicities                      Grade 2 Toxicities                    Grade 3 Toxicities
  Fatigue (acute and late) - 3 patients   Fatigue (acute) - 1 patient           Esophagitis (acute) - 1 patient
  Dermatitis (late) - 1 patient           Dermatitis (acute) - 1 patient         
  Voice change (acute) - 1 patient        Skin ulceration (acute) - 1 patient    
  Taste alteration (acute) - 1 patient                                           
  Pain (acute and late) - 1 patient                                              
  Dysphagia (late) - 1 patient                                                   
  Edema (late) - 1 patient                                                       
  --------------------------------------- ------------------------------------- ---------------------------------

Discussion
==========

Recurrence of HNC is a challenging clinical problem that often can lead to pain, suffering, and/or death \[[@REF19]\]. Current salvage therapies (surgery, chemotherapy, immunotherapy, conventional re-irradiation) have limited efficacy and potentially significant toxicities \[[@REF8], [@REF15]\]. SBRT allows for more conformal delivery of tumoricidal doses of radiation and has the potential for superior LC, OS, and quality of life as compared to conventional RT \[[@REF1]\].

On multivariate analysis, we found that patients treated with five-fraction SBRT who received doses ≥ 40 Gy had a significantly higher median OS (p = 0.028) and LC (p = 0.030) in comparison to those treated with \< 40 Gy. These results are consistent with other studies demonstrating an association between LC and OS with higher prescription doses \[[@REF1], [@REF5], [@REF20]\]. Rwigema et al. previously reported significantly improved three-year LC rates of 41.1% for patients treated with SBRT with prescription doses of 40 - 50 Gy as compared to 15.9% for those treated with less than 40 Gy \[[@REF5]\]. Also, a recent multi-institutional analysis by Vargo et al. found that rHNC patients with GTVs ≤ 25 cc treated with SBRT of doses \> 35 Gy had superior two-year OS rates compared to patients treated with doses \< 35 Gy (38.5% vs. 14.4%) \[[@REF1]\]. Our results also support tumor control probability data recently presented by the American Association of Physics in Medicine Working Group on Stereotactic Body Radiation Therapy (WGSBRT), which described a significant increase in LC and OS with dose escalation from 25 Gy to 40 Gy and recommended a minimum prescription dose of 40 Gy for all rHNC tumors treated with SBRT \[[@REF21]\]. 

To examine the effect of GTV on OS and LC and compare to previous literature, we used cutoffs of 25 cc and 50 cc, which is consistent with other studies examining relationships between GTV and OS during the primary course of therapy \[[@REF22]-[@REF23]\]. Our investigation did not find a statistically significant relationship between GTV and OS, nor between GTV and LC. This can be compared to Rwigema et al., who found no significant correlation between GTV and OS but did note a significant improvement in LC based on GTV ≤ 25 cc \[[@REF5]\].    

Among our cohort, the incidence of toxicity was relatively low, with 22.2% of patients reporting side effects. We found that 93.3% of these toxicities were Grade 1/2 with only one Grade 3 event of esophagitis occurring at two months post-treatment. These results are similar to the Phase I dose escalation study by Heron et al., which found no Grade 3/4 toxicities in a dose-escalation trial treating up to 44 Gy in five fractions over a two-week period \[[@REF4]\]. Our findings are further supported in a study by Rwigema et al., which found dose escalation up to 50 Gy in five fractions to be feasible with no Grade 4/5 toxicities present \[[@REF5]\]. However, our results did reveal a significant increase in toxicities following prescription doses ≥ 40 Gy for five-fraction SBRT (33.33%) as compared to \< 40 Gy (13.33%; p = 0.015) that was not found by Rwigema et al. \[[@REF5]\]. 

There are notable limitations to this study which merit attention. First, the smaller sample size resulting from our stringent selection criteria makes it challenging to generalize our findings to the general population. Second, data were censored for loss to follow-up during statistical analysis. Our study includes patients who were predominantly (89% of cohort) treated at community radiotherapy centers, which may contribute to differences in rates of follow-up and patient documentation compared to previous literature. Given the retrospective nature of the study, the lack of standardized follow-up limited the documentation of locoregional failures following SBRT and analyses examining LC. Additionally, while our rate of patient-reported toxicities is consistent with previous literature, the lack of homogenous follow-up increases the likelihood of under-reporting of toxicities. No information was available in the registry regarding initial disease staging, initial radiation therapy doses utilized, Epstein--Barr virus (EBV) status, human papillomavirus (HPV)/p16 staining on pathology, neoadjuvant, concurrent, or adjuvant chemotherapies or targeted therapies, the time between initial treatment and disease recurrence, or patient smoking status. Discrepancies in the diversity in our patient population are also notable, given that we have a higher than expected number of patients with nasopharyngeal disease despite few patients of Asian descent and a low number of African-American patients who normally bear a greater relative burden of HNC with poorer OS \[[@REF24]\].

Conclusions
===========

In this analysis, we provide a unique method to analyze outcomes of rHNC patients treated with SBRT across numerous institutions. Our findings demonstrate the efficacy of utilizing SBRT in the treatment of rHNC, showing improved patient outcomes when using prescription doses ≥ 40 Gy with subsequent increases in toxicity. Recent research demonstrates that the use of SBRT in conjunction with epidermal growth factor receptor (EGFR) inhibitors, such as cetuximab, display promising potential. As such, follow-up studies and clinical trials should examine patient outcomes using SBRT to treat rHNC at doses ≥ 40 Gy in combination with novel therapeutic agents. Further research should also be directed at determining if the increases in toxicity from doses greater than 40 Gy lead to changes in patient quality of life. Finally, this study provides further evidence that multi-institutional, community-focused databases can be effective tools in providing accurate, comparable information on the outcomes of patients with rHNC treated with SBRT. Also, our research provides further support for the notion that SBRT to doses of ≥ 40 Gy can safely be applied to patients with rHNC across a variety of clinical practice settings. Given its capability to compare and contrast patient outcomes data across multiple academic and private-practice settings, we suggest future analyses using the RSSearch Patient Registry to examine outcomes of additional treatment sites as the database accrues more clinical information. 

The authors have declared financial relationships, which are detailed in the next section.

John Vargo declare(s) personal fees from BrainLAB. John Vargo has previously received speaking honoraria from BrainLAB.

Consent was obtained by all participants in this study

**Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue.

We would like to thank all of the participating physicians, patients, and administrators of the RSSearch® Registry whose efforts made this study possible.
